Portaero still looking for $182K to treat emphysema
Portaero, developer of a device used to treat chronic obstructive pulmonary diseases — particularly emphysema — has raised the bulk of its targeted $12 million round of equity, according to regulatory filings. It is still short $182,000. Based in Cupertino, Calif., the company, which lacks a web site, has taken capital from Aberdare Ventures, Novartis Venture Funds and Versant Ventures.
Next Story: Vapore raises $348K to turn liquid medicines into vapors
Previous Story: M2 Group scores $6M for devices to treat diabetes
Tags: co:Portaero, inv:Aberdare-Ventures, inv:Novartis Venture Funds, inv:Versant-Ventures
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.